VivoSeq
Other

Insulin Secretion

55

Pipeline Programs↗

3

Active Trials↗

28

Companies Involved↗

Insulin Secretion is a moderately active landscape with 55 programs across 28 companies. The most active players are Merck & Co., Xeris Pharmaceuticals, Fresenius Kabi Oncology Ltd.. 14 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

6/100

Mech. Concentration

8/100

Completion Rate

83/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

3 programs

Phase 1X

Xeris Pharmaceuticals

1 program

Phase 1F

Fresenius Kabi Oncology Ltd.

1 program

Phase 1E

Eiger BioPharmaceuticals

1 program

Phase 1Z

Zydus Therapeutics Inc.

1 program

Phase 1Novo Nordisk logo

Novo Nordisk

3 programs

Phase 1

Pipeline

Programs by Phase

Preclinical10

Semaglutide

Novo Nordisk

Glimepiride

Sanofi

Paracetamol

GSK

Glyburide

Pfizer

Amlodipine

Viatris Specialty LLC

Phase 117

Glucagon

Xeris Pharmaceuticals

Atropine

Fresenius Kabi Oncology Ltd.

Exendin-(9-39)

Eiger BioPharmaceuticals

GLP-1 and GIP

The University of Texas Health Science Center at San Antonio

Insulin

Merck & Co.

Phase 210

Hydroxychloroquine

Alnylam Pharmaceuticals

Ibuprofen

Kenvue Brands

Verapamil

Val Adams

Diacerein

ANS Pharma

Anakinra or Rhifnγ

Hellenic Institute for the Study of Sepsis

Phase 34

Pantoprazole

Wyeth-Lederle Vaccines

Vildagliptin

Novartis

Nexium

Yooyoung Pharmaceutical Co., Ltd.

Exendin-9,39

Adrian Vella

Approved14

Dapagliflozin

AstraZeneca

Metformin

EMD Serono

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Tacrolimus

Veloxis Pharmaceuticals

Dexamethasone

Aspen Global Incorporated

Analysis

Modality Breakdown

92%

Small molecule

58 of 63 classified programs — the dominant modality here.

8%ALL OTHERSPeptide46%Monoclonal antibody12%

Small molecule leads; the ring shows all 63 classified programs, each share of the total. Modality classified for 100% of 65 pipeline programs.

Analysis

Trial Status

57

clinical trials

Completed39 · 68%
Unknown status7 · 12%
Withdrawn4 · 7%
Terminated4 · 7%
Recruiting2 · 4%
Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

57 trials

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00992901·160 enrolled
A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil
Recruiting·—·Phase 1/2·NCT07199946·36 enrolled
Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes.
Active, not recruiting·UUniversity of Guadalajara·Phase 2·NCT04341571·30 enrolled
The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion
Completed·WWashington University School of Medicine·Phase 1·NCT01951729·15 enrolled
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT01507311·11 enrolled
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01300260·32 enrolled
Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes
Completed·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT02127047·24 enrolled
Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes
Completed·YYaounde Central Hospital·Phase 4·NCT02832999·14 enrolled
Insulin Secretion in Diabetes Before and After Glycemic Control
Completed·US Department of Veterans Affairs·N/A·NCT00469833·17 enrolled
Pantoprazole on Insulin Secretion in Diabetes
Completed·CCoordinación de Investigación en Salud, Mexico·Phase 2/3·NCT01541735·14 enrolled
Diacerein on Insulin Secretion in Diabetes
Completed·CCoordinación de Investigación en Salud, Mexico·Phase 2·NCT01298882
Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.
Completed·UUniversity of Guadalajara·Phase 4·NCT02595684·18 enrolled
Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients
Completed·SSeoul National University Hospital·N/A·NCT02312375·46 enrolled
Influence of Central Nervous Insulin Sensitivity on Insulin Secretion
Completed·UUniversity Hospital Tuebingen·N/A·NCT02870361·15 enrolled
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
Completed·MMassachusetts General Hospital·Phase 1·NCT04958109·16 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)